← All trials
NCT05169697
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 21, 2022
- Primary completion
- Feb 21, 2024
- Completion date
- Feb 21, 2025
- First posted
- Dec 27, 2021
- Last posted
- Jul 22, 2022
- Enrollment
- 44
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eucure (Beijing) Biopharma Co., LtdLead sponsor
- Zhejiang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.